Does weight loss explain most of the cardiometabolic benefit?
Yes, the data strongly point to weight loss as the primary mechanism. In a large randomized controlled trial of 707 overweight men [2], researchers measured changes in physical activity, diet, sedentary time, and body weight over 12 months, then calculated how much each factor contributed to a combined cardiometabolic risk score (blood sugar, insulin, cholesterol, blood pressure). Weight change alone explained 14.1% of the improvement in that risk score, while changes in steps and diet together explained only about 4.5%. When weight was included in the model, the direct effects of diet and activity became very small. This means that even if GLP-1 drugs change what you buy and eat, the heart and metabolic benefits come mostly from the pounds you lose.
The same logic applies to GLP-1 medications. A comprehensive review [6] of GLP-1 agonists for obesity notes that these drugs improve hyperglycemia, insulin sensitivity, blood pressure, and provide cardiometabolic and renal protection — but these benefits are consistently linked to the 5% to 18% weight loss seen in trials [4][5]. The review does not claim that food-purchasing changes produce benefits independent of weight.
Do GLP-1 drugs actually change what people buy and eat?
Yes, they do, but the effect on cardiometabolic risk appears to run through weight loss rather than through diet quality alone. A joint advisory from four major medical societies [4][5] explains that GLP-1s alter dietary preferences and intakes — people tend to eat less ultra-processed, fatty, and sugary foods. This is consistent with a study [1] showing that higher intake of ultra-processed foods during pregnancy was linked to 31% higher odds of excessive weight gain and higher inflammation (C-reactive protein), suggesting that shifting away from such foods could improve health. However, the advisory [4][5] emphasizes that the main challenge is managing side effects, preventing nutrient deficiencies, and preserving muscle mass — not that food-purchasing changes independently lower heart risk.
The key point: changing what you buy is helpful because it helps you lose weight and keep it off, but the weight loss itself is what drives the cardiometabolic improvements. The lifestyle trial [2] found that even when people improved their diet and increased steps, those changes only mattered for heart risk to the extent they caused weight loss.
Is there any evidence of direct cardiometabolic benefits beyond weight loss?
There is some suggestive evidence, but it is not conclusive. A massive VA study [3] of over 215,000 people taking GLP-1 drugs compared to other diabetes medications found reduced risks for many conditions — including cardiometabolic disorders, coagulation problems, and even neurocognitive issues — but the study did not separate weight-dependent from weight-independent effects. It is possible that GLP-1s have direct anti-inflammatory or neuroprotective actions, but the study design cannot rule out that these benefits are simply downstream of weight loss.
The expert advisory [4][5] notes that GLP-1s have 'multiple demonstrated clinical benefits' beyond weight, but these are listed as part of the overall drug effect, not as effects independent of weight. The review [6] similarly highlights pleiotropic (multiple) effects of GLP-1 agonists, including improved insulin sensitivity and blood pressure, but again these are observed in the context of weight loss. No study among these six directly tested whether food-purchasing changes improve cardiometabolic risk independent of weight change — the closest is the lifestyle trial [2], which found that diet and activity changes had negligible direct effects once weight was accounted for.
About These Sources
This answer is built on 6 peer-reviewed studies — published from 2021 to 2025, 3 from 2024 or later, 6 in Q1 journals, collectively cited 541 times — selected as the most relevant from 6 studies that passed quality screening, drawn from 47 papers retrieved from a database of over 500 million.
Sources used in this answer
Associations of ultra-processed food intake with maternal weight change and cardiometabolic health and infant growth
In a US cohort of 458 pregnant women, each 1-standard-deviation higher intake of ultra-processed foods was linked to 31% higher odds of excessive weight gain and higher inflammation (C-reactive protein), suggesting diet quality affects weight and metabolic health.
Contributions of changes in physical activity, sedentary time, diet and body weight to changes in cardiometabolic risk
In a randomized controlled trial of 707 overweight men, weight change explained 14.1% of the improvement in cardiometabolic risk score, while changes in steps and diet explained only about 4.5% — and diet/activity effects largely disappeared when weight was accounted for.
Mapping the effectiveness and risks of GLP-1 receptor agonists
In a large VA cohort of 215,970 GLP-1 users compared to other diabetes drugs, GLP-1 use was associated with reduced risk of cardiometabolic disorders, but the study did not separate weight-dependent from weight-independent effects.
Nutritional priorities to support <scp>GLP</scp>‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society
A joint expert advisory from four major medical societies states that GLP-1s reduce body weight by 5% to 18% in trials and alter dietary preferences, but emphasizes that nutritional and lifestyle strategies are needed to manage side effects and preserve muscle — not that food changes independently improve cardiometabolic risk.
Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society
Same advisory as [4], published in a different journal, reiterating that GLP-1s change food intake and preferences but that weight loss is the primary driver of clinical benefits.
Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
A comprehensive review of GLP-1 agonists for obesity confirms they improve hyperglycemia, insulin sensitivity, blood pressure, and provide cardiometabolic protection, but these benefits are consistently linked to the weight loss they induce.